Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.

@article{Clarke2009EffectiveSO,
  title={Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.},
  author={Michelle J. Clarke and Evan A. Mulligan and Patrick Grogan and Ann C. Mladek and Brett L. Carlson and Mark A Schroeder and Nicola J Curtin and Zhenkun Lou and P. Anthony Decker and Wenting Wu and Elizabeth Ruth Plummer and Jann N. Sarkaria},
  journal={Molecular cancer therapeutics},
  year={2009},
  volume={8 2},
  pages={407-14}
}
Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1%, P = 0.005; GBM22: 54.4%, P = 0.043). ABT-888 had no effect with radiotherapy alone but… CONTINUE READING
29 Extracted Citations
24 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 29 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 24 references

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of GBM. Neuro-oncol 2005;7:164–76

  • C Giannini, J Sarkaria, A Saito
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…